Prestige Consumer Healthcare - PBH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $110.00
  • Forecasted Upside: 61.43%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$68.14
▼ -0.09 (-0.13%)

This chart shows the closing price for PBH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Prestige Consumer Healthcare Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PBH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PBH

Analyst Price Target is $110.00
▲ +61.43% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Prestige Consumer Healthcare in the last 3 months. The average price target is $110.00, with a high forecast of $117.00 and a low forecast of $103.00. The average price target represents a 61.43% upside from the last price of $68.14.

This chart shows the closing price for PBH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 polled investment analysts is to moderate buy stock in Prestige Consumer Healthcare. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/23/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/18/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$110.00 ➝ $103.00Low
11/15/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$124.00 ➝ $117.00Low
6/26/20233MReiterated RatingReiteratesLow
3/17/2023Royal Bank of CanadaLower TargetSector Perform$107.00 ➝ $104.00Low
2/17/2023OppenheimerLower TargetOutperform$72.00 ➝ $71.00Low
1/13/2023OppenheimerBoost TargetOutperform$63.00 ➝ $72.00Low
11/17/2022Canaccord Genuity GroupInitiated CoverageBuy$71.00Low
11/16/2022Canaccord Genuity GroupInitiated CoverageBuy$71.00Low
9/29/2022OppenheimerLower Target$63.00Low
8/9/2022DA DavidsonReiterated RatingNeutralLow
5/10/2022Jefferies Financial GroupUpgradeHold ➝ Buy$65.00 ➝ $70.00High
5/9/2022OppenheimerUpgradeMarket Perform ➝ Outperform$63.00High
11/15/2021DA DavidsonBoost TargetNeutral$61.00 ➝ $63.00High
11/5/2021Royal Bank of CanadaBoost TargetSector Perform$123.00 ➝ $126.00High
8/6/2021Royal Bank of CanadaBoost TargetSector Perform$107.00 ➝ $123.00N/A
8/6/2021DA DavidsonBoost TargetNeutral$52.00 ➝ $61.00High
5/28/2021DA DavidsonBoost TargetNeutral$49.00 ➝ $52.00Medium
5/10/2021DA DavidsonBoost TargetNeutral$39.00 ➝ $49.00High
12/2/2020BMO Capital MarketsUpgradeOutperform$125.00Low
11/9/2020CIBCBoost TargetNeutral$100.00 ➝ $103.00Medium
11/6/2020TD SecuritiesBoost TargetBuy$115.00 ➝ $125.00High
11/6/2020BMO Capital MarketsBoost TargetMarket Perform$106.00 ➝ $112.00High
11/6/2020DA DavidsonLower TargetNeutral$45.00 ➝ $39.00High
8/7/2020DA DavidsonDowngradeBuy ➝ Neutral$49.00 ➝ $45.00High
7/24/2020BMO Capital MarketsBoost TargetMarket Perform$91.00 ➝ $95.00Low
7/24/2020TD SecuritiesBoost TargetHold$90.00 ➝ $97.00Low
6/29/2020SidotiUpgradeNeutral ➝ Buy$46.00High
6/17/2020OppenheimerReiterated RatingHoldLow
5/12/2020CIBCBoost TargetNeutral$86.00 ➝ $88.00High
5/12/2020BMO Capital MarketsBoost TargetMarket Perform$85.00 ➝ $91.00High
4/15/2020DA DavidsonBoost Target$43.00 ➝ $47.00Medium
4/14/2020TD SecuritiesDowngradeHold$86.00High
4/14/2020Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
4/7/2020SidotiInitiated CoverageNeutralLow
3/26/2020Jefferies Financial GroupUpgradeHold ➝ Buy$43.00High
3/23/2020OppenheimerInitiated CoverageMarket PerformHigh
3/19/2020DA DavidsonUpgradeNeutral ➝ BuyHigh
2/7/2020DA DavidsonReiterated RatingNeutralHigh
1/30/2020BMO Capital MarketsBoost TargetOutperform$92.00 ➝ $106.00Low
5/27/2019CIBCReiterated RatingHold$84.00Medium
(Data available from 4/16/2019 forward)

News Sentiment Rating

1.17 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2023
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/18/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/17/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/17/2023
  • 5 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/16/2024
  • 14 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 14 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/16/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024

Current Sentiment

  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Prestige Consumer Healthcare logo
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Read More

Today's Range

Now: $68.14
Low: $67.84
High: $68.90

50 Day Range

MA: $70.48
Low: $62.88
High: $75.15

52 Week Range

Now: $68.14
Low: $55.96
High: $75.31

Volume

130,315 shs

Average Volume

208,864 shs

Market Capitalization

$3.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Prestige Consumer Healthcare?

The following Wall Street sell-side analysts have issued research reports on Prestige Consumer Healthcare in the last twelve months: 3M, BMO Capital Markets, Royal Bank of Canada, StockNews.com, and TheStreet.
View the latest analyst ratings for PBH.

What is the current price target for Prestige Consumer Healthcare?

2 Wall Street analysts have set twelve-month price targets for Prestige Consumer Healthcare in the last year. Their average twelve-month price target is $110.00, suggesting a possible upside of 61.4%. BMO Capital Markets has the highest price target set, predicting PBH will reach $117.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $103.00 for Prestige Consumer Healthcare in the next year.
View the latest price targets for PBH.

What is the current consensus analyst rating for Prestige Consumer Healthcare?

Prestige Consumer Healthcare currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PBH.

What other companies compete with Prestige Consumer Healthcare?

How do I contact Prestige Consumer Healthcare's investor relations team?

Prestige Consumer Healthcare's physical mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company's listed phone number is (914) 524-6800 and its investor relations email address is [email protected]. The official website for Prestige Consumer Healthcare is www.prestigebrands.com. Learn More about contacing Prestige Consumer Healthcare investor relations.